Press releases
How it works
Pricing
Alert the newsroom
Company, ID, topic
⌘K
EN
Sign in
Publish
a press release
Press releases
Company announcements, live
How it works
Publish in three steps
Pricing
Free, or Pro at €57.50 excl. VAT per month
Alert the newsroom
Share information without being identified
Publish a press release
Sign in
Search Clarsource
Company, SIREN, topic or press release title
Loading…
OSE Immunotherapeutics annonce des résultats positifs complémentaires de l'étude de Phase 2 randomisée Combi-TED de Tedopi® (OSE2101) dans le cancer du poumon non à petites cellules métastatique